In vitro studies show that Mps1 inhibitor cytotoxicities are ameliorated when combined with a cytostatic, selective CDK4/6 drug that pauses the cell cycle progression of normal cells while keeping tumor cells vulnerable to Mps1-mediated cell death. This evidence concerns the gene CDK4 and neoplasm.